CSIMarket
 
Taro Pharmaceutical Industries Ltd  (TARO)
Other Ticker:  
 
 
Price: $42.1400 $0.04 0.095%
Day's High: $42.21 Week Perf: 0.26 %
Day's Low: $ 41.96 30 Day Perf: -0.14 %
Volume (M): 68 52 Wk High: $ 45.76
Volume (M$): $ 2,853 52 Wk Avg: $36.27
Open: $41.96 52 Wk Low: $22.89



 Market Capitalization (Millions $) 1,584
 Shares Outstanding (Millions) 38
 Employees 5,860
 Revenues (TTM) (Millions $) 573
 Net Income (TTM) (Millions $) 25
 Cash Flow (TTM) (Millions $) -97
 Capital Exp. (TTM) (Millions $) 18

Taro Pharmaceutical Industries Ltd
Taro Pharmaceutical Industries Ltd is a leading global pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter (OTC) drugs for a range of therapeutic areas. Headquartered in Haifa Bay, Israel, Taro has a presence in more than 25 countries across North America, Europe, and Asia-Pacific. Established in 1950, the company has grown to become one of the top 10 generic drug manufacturers in the world.

Taro has a diverse portfolio of products that includes a wide range of topical creams, ointments, and gels; inhalers; tablets and capsules; liquids and pellets; and suspensions. The company's product portfolio spans multiple therapeutic categories, including dermatology, cardiology, gastroenterology, oncology, pediatrics, and urology. Some of its leading products include generic versions of Lotemax (loteprednol etabonate ophthalmic suspension), Ketoconazole Cream 2%, and the Lidocaine Patch 5%.

One of Taro's key strengths is its ability to deliver high-quality, affordable generics to customers around the world. The company has a state-of-the-art manufacturing infrastructure, which includes multiple research and development centers, manufacturing plants, and distribution centers. Taro's manufacturing facilities are located in Israel, Canada, and India, and are equipped with the latest technologies and processes to ensure high quality and efficiency. Its research and development centers are focused on developing new products and enhancing existing ones.

Taro's commitment to quality is reflected in its adherence to strict regulatory standards. The company has several regulatory approvals from the US FDA, Health Canada, and other regulatory agencies around the world. Taro's products are known for their efficacy, safety, and reliability, which has earned the company an enviable reputation in the global pharmaceutical industry.

Taro's success is also attributed to its strong corporate culture that is based on innovation, collaboration, and ethical practices. The company places a high value on its employees and invests in their development and wellbeing. Taro is committed to creating a diverse and inclusive work environment that fosters growth, innovation, and productivity. The company's ethical practices are reflected in its commitment to adhering to strict compliance standards and ensuring the safety and wellbeing of its patients and customers.

In summary, Taro Pharmaceutical Industries Ltd is a leading global pharmaceutical company that delivers high-quality, affordable generics to customers around the world. The company has a diverse portfolio of products, a state-of-the-art manufacturing infrastructure, and a strong commitment to quality, innovation, and ethical practices. Its continued growth and success in the global pharmaceutical industry are a testament to its unwavering commitment to excellence.


   Company Address: 14 Hakitor Street Haifa Bay 2624761 NY
   Company Phone Number: 345-9000   Stock Exchange / Ticker: NYSE TARO
   TARO is expected to report next financial results on June 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Taro Pharmaceutical Industries Ltd

Taro Pharma Records 2.07% Revenue Surge in Q1 2023 Despite Income Drop

Taro Pharmaceutical Industries Ltd, a major player in the pharmaceutical industry, recently released its financial report for the period ending March 31, 2023. While the report showed a decline in income of -56.13%, with net profits falling to $25.445 million, there is still reason to be optimistic about the company's future performance.
One positive aspect of the report is the rise in revenue of 2.07% compared to the previous financial reporting period. Despite the income decline, this increase in revenue shows that Taro Pharmaceutical Industries Ltd has been successful in generating sales and attracting customers. The company's revenue for the period was $572.95 million, a significant improvement from $561.33 million in the previous year.






 

Taro Pharmaceutical Industries Ltd's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com